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Objective: The aim of this work was to demonstrate a possible relationship between anti-
latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-1)
expression in megakaryocytes and microvascular density in bone marrow biopsies from
patients with essential thrombocythemia and primary myeloﬁbrosis.
Methods: Microvascular density was evaluated by immunohistochemical analysis and the
expression of latent TGF-1 in samples (100 megakaryocytes per bone marrow sample) from
18  essential thrombocythemia and 38 primary myeloﬁbrosis (19 preﬁbrotic and 19 ﬁbrotic)
patients. Six bone marrow donor biopsies were used as controls. Fibrosis in the bone marrow
biopsies was evaluated according to the European Consensus.
Results: The average ﬁbrosis grade differed between essential thrombocythemia and
primary myeloﬁbrosis groups when compared to the control group. Latent TGF-1 expres-
sion  differed signiﬁcantly between the ﬁbrotic primary myeloﬁbrosis (PMF) group and the
control group (p-value < 0.01). A high degree of neo-angiogenesis (demonstrated by analysis
of  CD34 expression) was detected in patients with myeloﬁbrosis. There were correlations
between latent TGF-1 expression and microvascular density (r = 0.45; p-value < 0.0009)
and between degree of microvascular density and ﬁbrosis grade (r = 0.80; p-value < 0.0001).
Remarkable differences for neo-angiogenesis were not observed between patients with
essential thrombocythemia and controls.
Conclusion: Angiogenesis participates in the pathogenesis of primary myeloﬁbrosis, in both
the  preﬁbrotic and ﬁbrotic stages, while latent TGF- is differentially expressed only in the
preﬁbrotic stage.o Bra© 2014 Associac¸ã∗ Corresponding author at: Universidade Federal de São Paulo, Campus S
Santos,  SP, Brazil.
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hronic myeloproliferative neoplasms (MPNs) were catego-
ized for the ﬁrst time in 1951 by William Dameshek, who
oticed phenotypic similarities and characteristics common
o chronic myeloid leukemia (CML), polycythemia vera (PV),
ssential thrombocythemia (ET) and primary myeloﬁbrosis
PMF).1
PMF  is a clonal stem cell disorder that is characterized by
one marrow myeloproliferation associated with a stromal
eaction, including ﬁbrosis, osteosclerosis and angiogenesis.2
Of the different types of MPN,  PMF  is associated with
he worst prognosis; the primary causes of death are throm-
ohemorrhagic events, bone marrow failure and leukemic
ransformation. The median survival ranges from two to over
5 years and varies according to the stage: preﬁbrotic or
brotic.3
According to the World Health Organization (WHO), the
ajor differential criterion between ET and PMF  is ﬁbrosis,
hich is either minimal or absent in ET patients and present
o various degrees in PMF  patients.4
The classiﬁcation of bone marrow ﬁbrosis by the European
onsensus involves an assessment of the stroma and bone
haracteristics on a scale that ranges from 0 to 3. Grade zero
orresponds to few linear reticulin, Grade 1 to a few ﬁber inter-
ections in focal areas around vessels, Grade 2 to a diffuse
ncrease in reticulin, many  intersections and some foci of col-
agen or osteosclerosis and Grade 3 to conspicuous and diffuse
ncreases in reticulin ﬁbers, many  ﬁber intersections, collage-
ization and osteosclerosis.5
Special stains are necessary to identify and classify bone
arrow ﬁbrils. Mallory and Masson stains are used for colla-
en I while silver (Gomori) is used for reticulin ﬁbers.6–9
Another histological feature observed in PMF is increased
ngiogenesis. Angiogenesis is the generation of new blood
essels from the pre-existing vasculature.2
In PMF,  angiogenesis seems to be associated with stromal
brosis triggered by the release of several cytokines produced
y megakaryocytes, including transforming growth factor-
eta (TGF-).10
TGF- is a multifunctional cytokine with three isoforms:
GF-1, TGF-2 and TGF-3, with TGF-1 being the most
bundant.11 TFG- is synthesized as an inactive form (latent
GF-) by various cells (epithelial, endothelial, hematopoi-
tic, neuronal cells and connective tissue).12 Platelets and
egakaryocytes are an abundant source of TGF-1 in
umans.11
For TGF- to signal through its receptors, it must be con-
erted into the active state; once activated, this cytokine acts
n target cells, thereby producing different effects depending
n the cell type and on the degree of differentiation of the
ell.13–15
Of the several functions of TGF-, the stimulation of
xtracellular matrix production and angiogenesis should be
ighlighted.
Fibroblasts display TGF- receptors, which are stimulated
o produce structural proteins, primarily collagen.12,14 TGF-
lso inhibits the synthesis of extracellular matrix proteases
nd is therefore involved in the pathogenesis of diseases asso-
iated with the over deposition of connective tissue.10 1 4;3  6(5):322–328 323
Endothelial cells (ECs) signal via two different type I recep-
tors, also known as activin receptor-like kinases (ALK), with
opposite effects. While the activation of ALK5 by TGF-
results in the inhibition of migration and proliferation, TGF-
-induced ALK1 activation results in the increased migration
and proliferation of ECs. Both ALK1 and ALK5 are functional
TGF- type I receptors in ECs. The ratio of TGF- signals via
ALK1 versus ALK5 determines whether TGF- exerts pro- or
anti-angiogenic effects.16
TGF- is also an indirect angiogenic factor promot-
ing angiogenesis via the downstream induction of other
cytokines, such as vascular endothelial growth factor (VEGF).17
VEGF is a potent, direct-acting regulator of angiogenesis that
is detectable in various types of malignancies.18,19
Angiogenesis is essential in the pathogenesis of PMF,
while it is less pronounced in PV and ET.18 The increase
in microvascular density (MVD) in PMF correlates with cel-
lularity and megakaryocytes clusters. Clonal proliferation
of megakaryocytes in PMF is accompanied by an abnormal
release of cytokines, including angiogenic factors, resulting in
an excessive stromal reaction and an increase in bone marrow
vascularity.20
Because megakaryocytes and platelets are a major source
of TGF-1, which is able to enhance collagen synthesis and
vessel proliferation, it is thought to be one of the key cytokines
involved in the development of primary myeloﬁbrosis.9
The aim of this work was to demonstrate a possible rela-
tionship between latent TGF-1 expression in megakaryocytes
and MVD  as assessed by immunohistochemical analysis of
bone marrow biopsies from ET and PMF patients. As ﬁbrosis
is used to differentiate between ET and PMF,3 possible asso-
ciations between MVD,  ﬁbrosis and latent TGF-1 expression
were evaluated.
Methods
The study was conducted using bone marrow biopsy sam-
ples collected from 56 patients with either ET or PMF.  Samples
from six bone marrow donors were used as normal controls.
Patients previously evaluated for the relationship between
TGF-1 and bone marrow ﬁbrosis21 were the participants in
this study. All patients were examined in the Hematology and
Pathology Departments of Hospital São Paulo, Universidade
Federal de São Paulo between 1992 and 2010. Participants were
included in the study after informed consent was obtained
according to the guidelines of the Institutional Ethics Com-
mittee.
The clinical, cytological and histological aspects of all cases
were reviewed and classiﬁed according to WHO  criteria3 before
being selected for the study. The cases were selected based on
the diagnosis by biopsy and before the patient had started any
type of therapy.
Subjects were divided into four groups: 18 cases of ET;
38 cases of PMF, which included 19 cases at each phase
(preﬁbrotic PMF  and ﬁbrotic PMF); and six controls. The con-disease-free and were on the bone marrow donor registry. Two
cases of reactive thrombocytosis were used as controls for the
immunohistochemistry test.
oter. 2 0 1 4;3  6(5):322–328
Table 1 – Immunohistochemical evaluation of latent
TGF-1 antibodies in the control, essential
thrombocythemia and primary myeloﬁbrosis samples.
A B
Positivity (%) Intensity
0 Negative (0–10) 0 – negative
1 Slight (11–25) 1 – weak
2 Intermediate (26–50) 2 – moderate
3 Extensive (over 50) 3 – strong324  rev bras hematol hem
The bone marrow biopsy tissue was ﬁxed in 10% buffered
formalin, processed according to conventional histological
techniques and embedded in parafﬁn. Two-micrometer thick
sections were submitted to the following staining protocols:
hematoxylin-eosin (HE), Giemsa (GM) and Gomori’s silver
impregnation (reticulin). Fibrosis was evaluated in accordance
with the European Consensus Criteria.5 The histological slides
were independently analyzed by two pathologists, with cases
for which agreement was not consensual being discussed.
Goat IgG polyclonal anti-LAP human TGF-1 (R&D Sys-
tems – AF-246-NA), and mouse IgG1 kappa monoclonal
anti-CD-34 Class II antibodies (Dako-M7165 – QBEnd 10)
were used for immunohistochemistry. The bone marrow
sections were processed in xylene and alcohol for deparaf-
ﬁnization, and were blocked for endogenous peroxidase
activity (ﬁve times). The samples were incubated in a 1:100
dilution of the primary antibodies for 18 h at 4 ◦C, and
Biotin Link was used as a secondary antibody for 40 min
followed by streptavidin-peroxidase treatment. Visualiza-
tion was achieved with diaminobenzidine chromogen and
counter-staining using Harris hematoxylin.
Latent TGF-1 antibody expression was evaluated via light
microscopy of 100 megakaryocytes per case to determine pos-
itivity and intensity.
Positivity was assessed using a grading system ranging
from 0 to 3 based on the percentage of positive cells (Table 1A).
Immunoexpression intensity was designated as negative,
weak, moderate, or strong on a scale from 0 to 3 (Table 1B). A
ﬁnal score for latent TGF-1 immunostaining was obtained by
multiplying the two analyzed variables (positivity and inten-
sity), the values of which ranged from 0 to 9s21–23 (Table 1 and
Fig. 1).
Angiogenesis was assessed in 14 cases of ET, 32 cases of
PMF  (18 preﬁbrotic and 14 ﬁbrotic phases), and ﬁve controls.
Figure 1 – Photomicrograph of latent transforming growth factor
patients (essential thrombocythemia and primary myeloﬁbrosis)
(B) weak (1), (C) moderate (2), and (D) strong (3) (arrow).Score: (positivity) × (intensity).
Two different methods were used for this assessment:
(1) Estimating angiogenesis (microvessel grade)
Angiogenesis was evaluated in each bone marrow sample
by two independent reviewers using visual microves-
sel grading. Speciﬁcally, slides were visually scanned
at 100×, 200× and 400× magniﬁcation and were semi-
quantitatively graded for vessels by CD34 staining using a
light microscope. Each specimen was graded on a semi-
quantitative scale: microvessel Grade 1, scarce vessels;
Grade 2, diffuse slight increase in vessels; Grade 3, areas
with marked increases in vessels; and Grade 4, extensive
increases in vessels20,24 (Fig. 2).
(2) Microvascular density
Immunostaining for the CD34 antigen was used to eval-
uate the vessels in the bone marrow biopsy sections. The
absolute number of CD34-positive vascular structures was
recorded in ﬁve randomly selected ﬁelds at 400× magniﬁ-
cation for each case by light microscopy. Microvessels were
identiﬁed as ECs appearing as a single cell or cells clus-
tered in the network or tubes either with or without lumen.
Sinusoids were included in the count, while arterioles
-beta 1 immunoexpression (400×) in the controls and
 according to the intensity of the reaction: (A) negative (0),
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Figure 2 – Photomicrograph of the microvessel grade for CD34 immunoexpression (400×): (A) Grade 1, (B) Grade 2, (C) Grade
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were excluded. MVD  was calculated as the median value
of vascular structures and used for statistical analysis.25–27
The score assigned to the immunoexpression results of
nvestigated antigens were compared between the differ-
nt groups: control, ET, preﬁbrotic PMF  and ﬁbrotic PMF.
he results were assessed using the Kruskal–Wallis non-
arametric test followed by post hoc Dunn’s test to identify
igniﬁcant differences between the groups. The correlation
etween the degree of ﬁbrosis, latent TGF-1 immunoexpres-
ion, angiogenesis by estimating microvessel grade, and MVD
n the groups and all cases studied was analyzed with the
pearman test. p-values ≤ 0.05 were considered statistically
igniﬁcant.
esults
he average age of the patients with ET and PMF was approx-
mately 20 years greater than the average age of the subjects
n the Control Group. There was no difference associated with
ender among PMF  cases, while there was a predominance of
omen in the ET group.
The degree of ﬁbrosis and latent TGF-1 immunoexpres-
ion in megakaryocytes based on the positivity and intensity
riteria in each group and the ﬁnal score obtained are pre-
ented in Table 2.
As shown in Table 2, the criterion positivity for latent
GF-1 expression shows a tendency of extensive immuno-
xpression in all groups, while the intensity is stronger in the
reﬁbrotic PMF  group and varies from ‘weak’ in the control
nd ET groups to ‘moderate’ in the ﬁbrotic PMF  group.
The score was signiﬁcantly lower in the controls compared
o the preﬁbrotic PMF  group (p-value < 0.01). The analysis with
he ET group showed no signiﬁcant difference.The reticulin graduation (ﬁbrosis) for each group is listed
in Table 2. There were signiﬁcant differences in the grade
of ﬁbrosis between groups and in the latent TGF-1 score
between the control and preﬁbrotic PMF groups (p-value < 0.01)
(Fig. 3).
The distribution of microvessels and the MVD  values
for both patients and controls are shown in Fig. 3 and
Table 3.
Dunn’s multiple comparison test demonstrated that
patients with ﬁbrotic PMF had signiﬁcantly higher MVD  val-
ues than those with ET (p-value < 0.001) and the controls
(p-value < 0.001), and patients with preﬁbrotic PMF  also had
higher values for MVD compared to the ET (p-value < 0.01) and
control groups (p-value < 0.001) (Fig. 3 and Table 3).
The Spearman correlation between MVD and the estima-
tion of angiogenesis (microvessel grade) was demonstrated for
each group (ET, preﬁbrotic PMF  and ﬁbrotic PMF).
It was impossible to assess the relationship for the
control group because the estimation for angiogenesis in
this group did not change. An intermediate correlation
(r = 0.61; p-value < 0.0181) was observed for the ET group and
strong correlations were observed for the preﬁbrotic PMF
(r = 0.90; p-value < 0.0001) and ﬁbrotic PMF  groups (r = 0.83; p-
value < 0.0002).
The correlation coefﬁcient was also evaluated between
each variable analyzed in this study considering the total
number of cases.
Strong correlations were found on comparing MVD  with
microvessel grade (r = 0.92; p-value < 0.0001), MVD  with degree
of ﬁbrosis (r = 0.80; p-value < 0.0001) and microvessel grade
with ﬁbrosis grade (r = 0.77; p-value < 0.0001). The correlation
of the latent TGF-1 score with MVD (r = 0.45; p-value < 0.0009)
and with the microvessel grade (r = 0.46; p-value < 0.0006) was
also demonstrated.
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Table 2 – Latent TGF-1 evaluation and ﬁbrosis grade in the control, essential thrombocythemia, preﬁbrotic and ﬁbrotic
primary myeloﬁbrosis groups.
Control ET Preﬁbrotic PMF Fibrotic PMF
n = 6 n = 18 n = 19 n = 19
Latent TGF-ˇ1 positivity – n (%)
Negative – – – –
Discrete 1 (16.67) – – –
Intermediate 1 (16.67) 2 (11.11) 2 (10.52) 1 (5.27)
Extensive 4 (66.67) 16 (88.89) 17 (89.48) 18 (94.73)
Latent TGF-ˇ1 intensity – n (%)
Negative – – – –
Weak 6 (100.00) 8 (44.44) 4 (21.05) 6 (31.58)
Moderate – 5 (27.78) 3 (15.79) 8 (42.11)
Strong – 5 (27.78) 12 (63.16) 5 (26.31)
Latent TGF-ˇ1 score – n (%)
Zero – – – –
One 1 (16.67) – – –
Two 1 (16.67) 2 (11.11) 2 (10.52) 1 (5.27)
Three 4 (66.67) 6 (33.33) 2 (10.52) 5 (26.31)
Six – 5 (27.78) 3 (15.79) 8 (42.11)
Nine – 5 (27.78) 12 (63.16) 5 (26.31)
Latent TGF-ˇ1 score
mean (±SD)
2.50  (±0.83)a 5.39 (±2.70) 7.15 (±2.71)a 5.79 (±2.41)
Fibrosis grade – n (%)
Zero 5 (83.33) – – –
One 1 (16.67) 12 (66.67) 1 (5.27) –
Two – 5 (27.78) 16 (84.21) –
Three – 1 (5.55) 2 (10.52) 19 (100.00)
Fibrosis grade
mean (±SD)
0.17  (±0.40)a 1.39 (±0.60)a 2.05 (±0.40)a 3.00 (±0.00)a
ET: essential thrombocythemia; PMF: primary myeloﬁbrosis; TGF-1: transforming growth factor-beta 1; SD: standard deviation.
a p-value < 0.01.
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Table 3 – Microvessel grade and microvascular density in the control, essential thrombocythemia, preﬁbrotic and ﬁbrotic
primary myeloﬁbrosis groups.
Control ET Preﬁbrotic PMF Fibrotic PMF
n = 5 n = 14 n = 18 n = 14
Microvessel grade – n (%)
One 5 (100.00) 1 (7.14) – –
Two – 12 (85.72) 6 (33.33) –
Three – 1 (7.14) 7 (38.89) 5 (35.71)
Four – – 5 (27.78) 9 (64.29)
Microvessel grade
Mean (±SD)
1.00 (±0.00)a 2.00 (±0.39)a 2.94 (±0.80)a 3.64 (±0.49)a
Microvessel density
Mean (±SD)
0.72 (±0.17)a 2.42 (±0.69)a 6.46 (±3.53)a 8.78 (±1.94)a
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a p-value < 0.05.
iscussion
he increase in stromal ﬁbrosis is evident in chronic myelopro-
iferative neoplasms albeit with a variable course depending
n the speciﬁc subtype.3 Fibrosis seems to be associated with
bnormalities in the number and function of megakaryocytes
nd platelets.9
The primary histological feature common to PMF and
T cases is megakaryocytic hyperplasia with nuclear atypia,
hile ﬁbrosis represents the major differential criteria
etween the two diseases.3 Megakaryocytes and platelets pro-
uce high levels of TGF-1.9
It has been postulated that defective or abnormal
egakaryocytes with higher immunoexpression of the latent
orm of TGF-1 are involved in the development of myeloﬁ-
rosis and angiogenesis.10,21
In the present study, we  showed that the mean latent TGF-
1 immunoexpression levels and degree of ﬁbrosis were lower
n the control group than in the preﬁbrotic PMF  group (p-
alue < 0.01). The differences in the microvessel grade and
VD  between these groups are also signiﬁcant (p-value < 0.01),
uggesting that TGF-1 is a common factor in both situations.
Panteli et al.18 and Steurer et al.26 assessed MVD in
hronic myeloproliferative neoplasms by examining CD34
mmunoexpression and demonstrated that neo-angiogenesis
s increased in both phases of PMF  (preﬁbrotic and ﬁbrotic)
ompared to cases of PV, and ET and controls. The outcome of
hese studies is in agreement with our ﬁndings.
In this study, the use of two methods to assess angio-
enesis, estimating angiogenesis by examining microvessel
rade20,24 and MVD,25–27 aimed to improve the credibility of
he results.
The two approaches were in agreement with similar results
f the differentiation of the groups (control, ET, preﬁbrotic PMF
nd ﬁbrotic PMF) with p-values ≤ 0.05 (Fig. 3) and a strong cor-
elation coefﬁcient between microvessel grade and MVD with
-value < 0.0001 and r = 0.92. This overlap of the results shows
hat estimating angiogenesis (microvessel grade) in bone mar-
ow biopsies can be as accurate as evaluating the MVD,  thereby
alidating this simple method for use in the routine practice.
In the development of scar ﬁbrosis, neo-angiogenesis pro-
otes the deposition of collagen,28 with TGF-1 being one
ytokine involved in these events.29 Our study showed a cleardeviation.
correlation between angiogenesis and ﬁbrosis, even though
the association between the expression of TGF-1 and vascu-
larization was only moderate.
In our histological evaluation of ﬁbrotic PMF  cases, there
was very low cellularity including decreased numbers of
megakaryocytes, resulting in decreased latent TGF-1 immu-
noexpression in the ﬁbrotic phase which may explain the
absence of any correlation between this cytokine and ﬁbrosis.
On the other hand, induction of angiogenesis and ﬁbrogenesis
by TGF-1 acting in the preﬁbrotic stage becomes obvious in
the histological features of the ﬁbrotic phase.21
Moreover, latent TGF-1 immunoexpression correlated
with angiogenesis as assessed using the two methods, MVD
(r = 0.45; p-value < 0.0009) and microvessel grade (r = 0.46; p-
value < 0.0006). These results may be associated with the
dynamics of the healing process, in which the involvement
of inﬂammatory cytokines and growth factors, particularly
TGF-1, prior to the neo-angiogenesis stage represents an
intermediate phase in the establishment of interstitial ﬁbrosis.
Moreover, we believe that there are other special features
involved in the development of stromal ﬁbrosis associated
with primary myeloﬁbrosis, such as other growth factors
(platelet-derived growth factor, ﬁbroblast growth factor) or
cytokines (interleukin-1, tumor necrosis factor), which require
further investigation.
Conclusions
A correlation was observed between latent TGF-1 immu-
noexpression and neo-angiogenesis, which precedes the
establishment of bone marrow stromal ﬁbrosis. A highly reli-
able method to estimate angiogenesis (microvessel grade) was
also demonstrated; this technique is easier than MVD and as
accurate and can be used to assess microvasculature in bone
marrow biopsies.
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